Tag: managers

Brisbane, QUEENSLAND, June 04, 2026 (GLOBE NEWSWIRE) -- Orange Plan Management, an Australian NDIS plan management provider, announced today that it has achieved a 4.9-star Google rating across more than 50 customer reviews, marking a significant company milestone. The achievement reinforces Orange Plan Management's position as a leading NDIS plan manager in Australia and reflects consistent feedback from participants and support networks regarding the company's responsive service, timely provider payments, and ongoing commitment to supporting NDIS participants nationwide.

SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- SOLV Energy, Inc. (“SOLV” or the “Company”) (Nasdaq: MWH), a leading provider of infrastructure services to the power industry, today announced that, in connection with its previously completed public offering of 15,000,000 shares of Class A common stock of the Company, including 7,698,410 shares being offered by affiliates of American Securities LLC (the “Selling Stockholders”) and 7,301,590 shares being offered by the Company, the underwriters have fully exercised their option to purchase an additional 2,250,000 shares of Class A common stock of the Company, including 1,154,760 shares from the Selling Stockholders and 1,095,240 from the Company at the public offering price of $36.00 per share, less underwriting discounts and commissions. The issuance and sale of the additional shares closed today.

TORONTO, June 04, 2026 (GLOBE NEWSWIRE) -- Lysander Funds Limited (“Lysander”), the manager of Canso Credit Income Fund (the “Fund”) (TSX: PBY.UN), announces that, at the special meeting of unitholders of the Fund held on June 4, 2026, unitholders of each class of the Fund have approved a change in the structure of the Fund from a closed-end fund into an exchange-traded fund (the “Conversion”), along with other related changes necessary to facilitate and implement the Conversion.

MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced the pricing of its upsized underwritten public offering of $500,000,000 aggregate principal amount of its 0.250% convertible senior notes due 2032 (the “Convertible Notes”). The aggregate principal amount of the offering was increased from the previously announced offering size of $400,000,000.

Upcoming index suite transforms global news, macroeconomic developments and geopolitical events into actionable sentiment signals for investors and trading teams.